BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.720
+0.010 (0.58%)
Apr 28, 2025, 4:00 PM EDT - Market closed
BioRestorative Therapies Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BioRestorative Therapies stock has a target of 18, which predicts an increase of 946.51% from the current stock price of 1.72.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 14, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for BioRestorative Therapies is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $15 → $18 | Strong Buy | Maintains | $15 → $18 | +946.51% | Aug 14, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +772.09% | Jun 12, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +772.09% | Aug 14, 2023 |
| Roth Capital | Roth Capital | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +772.09% | Dec 7, 2022 |
| Maxim Group | Maxim Group | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +248.84% | Sep 28, 2022 |
Financial Forecast
Revenue This Year
2.19M
from 401.00K
Increased by 446.88%
Revenue Next Year
3.06M
from 2.19M
Increased by 39.53%
EPS This Year
-1.29
from -1.16
EPS Next Year
-0.85
from -1.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.4M | 3.7M | 98.9M | ||
| Avg | 2.2M | 3.1M | 49.6M | ||
| Low | 2.0M | 2.5M | 3.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 502.2% | 67.6% | 3,133.1% | ||
| Avg | 446.9% | 39.5% | 1,522.5% | ||
| Low | 388.8% | 11.7% | 0.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.13 | -0.86 | 3.07 | ||
| Avg | -1.29 | -0.85 | 1.13 | ||
| Low | -1.41 | -0.82 | -0.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.